Photobiomodulation is the mechanism by which non-ionizing optical radiation in the visible and near-infrared spectral range is absorbed by endogenous chromophores to elicit photo-physical and photo-chemical events at various biological scales. Photobiomodulation Therapy (PBMT) is a form of light therapy based on the principles of photobiomodulation. It involves the use of light sources including lasers, LEDs, and broadband light, in the visible and infrared spectrum to cause physiological changes and therapeutic benefits. PBMT has the potential to revolutionize modern healthcare and is being used by veterinarians, dentists and physical therapists for a number of applications including tissue regeneration, pain relief and regulation of inflammation. New areas of research include as age-related macular degeneration, spinal cord injury, and traumas and pathologies of the brain. The focus of the OSA Photobiomodulation Technical Group will be to develop guidelines to help ensure safety, efficacy and scientific accuracy in photobiomodulation research and technology development.
CLEO: 2017 Report
A specialized session focused on “Photobiomodulation Therapeutics” was organized and presented in the CLEO: 2017 A&T Biomedical Applications Track on 16 May. The session was chaired by Dr. Ilko Ilev and included invited and contributed papers presented by distinguished experts worldwide on the recent developments in the areas of photobiomodulation (PBM) therapeutics and other medical device applications. Professor Juanita Anders gave a key invited talk entitled “Emerging Photobiomodulation Therapeutics”. Dr. Ilev also present a talk focused on PBM mechanisms entitled “Label-free sensing of intrinsic biomarkers related to medical device performance employing a noninvasive fingerprint infrared spectroscopy method.” This is the first time that a session on Photobiomodulation Therapeutics was presented at CLEO, which is a premier international forum for scientific and technical optics, sponsored by APS Physics, IEEE Photonics, and The Optical Society (OSA). Dr. Ilev is Vice-Chair of the OSA Photobiomodulation technical group and has been named as the Subcommittee Co-Chair CLEO A&T 1: Biomedical Applications for 2018. Committee Members of the 2018 CLEO A&T1 are also Dr. Brian Pryor, LiteCure, and Dr. Sean Wang, B&W Tek, who have also been actively involved in the Photobiomodulation field. In this capacity, Dr. Ilev is planning on enlarging the presence of Photobiomodulation Therapeutics at the CLEO: 2018 conference by organizing several focused events highlighting this important area of optical therapeutics.
||U.S. Food and Drug Administration||Vice Chair
||American Institute of Medical Laser Appl||Events Officer
||Academy of Laser Dentistry||Events Officer
||THOR Photobiomodulation Ltd||Social Media Officer
|| ||Social Media Officer
||University at Buffalo||Webinar Officer
||Harvard Medical School||Webinar Officer
24 October 2017
Hyatt Regency Osaka
17 November 2017
Hampton Inn Tropicana
17 November 2017
United Arab Emirates
17 November 2017
27 February 2018
Networking with the Biomedical Optics Technical Groups
Wednesday, 20 September 2017, 18:30 – 20:00
The Photobiomodulation Technical Group, in conjunction with the Therapeutic Laser Applications Technical Group and Tissue Imaging and Spectroscopy Technical Group, will host a happy hour networking event to provide researchers the opportunity to meet other researchers in biomedical optics. Refreshments will be provided; please RSVP to firstname.lastname@example.org
if you plan to attend this networking event.
Become a members of our newest technical group today! OSA Members can join the Photobiomodulation Technical Group by updating their profile in My Account.
Join the Photobiomodulation Techical Group >>
In 2015, leaders of this technical group hosted an OSA Incubator Meeting
focused on the discussion and dissemination of scientifically sound research in the field of Photobiomodulation. You can read more about this meeting in the following blog posts:
, an OSA Fellow, played an instrumental role in establishing the credibility of Photobiomodulation in the academic community and funding agencies in the United States. His sad passing in 2016 is a great loss to the Photobiomodulation community.
Join our Online Community